← Back to Search

Physostigmine for Smoking (nic_physo Trial)

N/A
Waitlist Available
Led By Kelly Cosgrove, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
have no history of a neurological or psychiatric disorder (DSMIV Axis 1 and 2) other than schizophrenia in schizophrenia subgroup
who are able to read and write
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration
Awards & highlights

nic_physo Trial Summary

This trial will measure the effects of smoking and schizophrenia on the availability of nicotinic receptors and dopamine levels.

Eligible Conditions
  • Smoking
  • Schizophrenia

nic_physo Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

nic_physo Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images.
Change in Dopamine (DA) Levels After Amphetamine Administration as Confirmed by PET Images.

Side effects data

From 2020 Phase 4 trial • 19 Patients • NCT03090620
11%
Vomitnig
11%
Oversedation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Physostigmine
Lorazepam

nic_physo Trial Design

1Treatment groups
Experimental Treatment
Group I: physostigmine and amphetamineExperimental Treatment1 Intervention
There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Physostigmine
2009
Completed Phase 4
~150

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,453 Previous Clinical Trials
2,596,726 Total Patients Enrolled
66 Trials studying Smoking
22,540 Patients Enrolled for Smoking
Yale UniversityLead Sponsor
1,839 Previous Clinical Trials
2,728,963 Total Patients Enrolled
32 Trials studying Smoking
9,590 Patients Enrolled for Smoking
National Institutes of Health (NIH)NIH
2,682 Previous Clinical Trials
6,930,718 Total Patients Enrolled
35 Trials studying Smoking
14,135 Patients Enrolled for Smoking

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Mar 2025